Drugs / XH-02
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07530705 | Nov 2025 → May 2026 overdue | hypoparathyroidism | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07540286 | Apr 2026 → Apr 2030 expected | hypoparathyroidism | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XH-02 | “XH-02 is an mRNA nucleic acid drug that expresses PTH in the body following intravenous or subcutaneous injection, providing PTH replacement therapy for patients with...” NCT07530705 ↗1“Participants will receive a single dose of XH-02 through subcutaneous injection.” NCT07540286 ↗ |
| Action | Restore | “providing PTH replacement therapy” NCT07540286 ↗ |
| Modality | Messenger RNA (mRNA) | “XH-02 is an mRNA nucleic acid drug” NCT07530705 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT07530705 ↗ |